MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach

    S. Jain (Gandhinagar, India)

    Objective: Parkinson's disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests…
  • 2024 International Congress

    Effect of Tactile Cueing on Dual Task Performance in Parkinson’s Disease-A Systematic Review and Meta-Analysis

    V. Azoidou, A J. Noyce, C. Simonet (London, United Kingdom)

    Objective: This systematic review and meta-analysis were performed to examine the effect of tactile cueing on dual task (DT) performance in adults with idiopathic Parkinson’s…
  • 2024 International Congress

    If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply

    D. García-Meléndez, E. Gisbert Tijeras, B. Carmona Moreno, E. Botia Paniagua (Alcázar San Juan, Spain)

    Objective: Include inhaled levodopa as a therapeutic option in those patients who, due to post-surgical problems, cannot use oral treatments. Background: The development of motor…
  • 2024 International Congress

    Beta peaks as predictor for DBS outcome in Parkinson’s disease

    V. Molinari, M. Sure, E. Florin, C. Hartmann, A. Schnitzler (Düsseldorf, Germany)

    Objective: Determining the relevance of subthalamic (STN) beta peaks in Parkinson's disease (PD) patients with deep brain stimulation (DBS) in relation to the best possible…
  • 2024 International Congress

    The impact of multimodal forms of art therapy on treatment outcomes and quality of life in Parkinson’s disease

    L. čondić Jurjević, S. Telarović (Sisak, Croatia)

    Objective: Assessing the impact of art therapy on treatment outcomes and quality of life in Parkinson's disease (PD). Background: In addition to medical treatment, art…
  • 2024 International Congress

    Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease

    XD. Yang, Q. Xiao, XQ. He (Shanghai, China)

    Objective: We sought to determine whether fecal bile acids (BAs) could affect levodopa response assessed by levodopa challenge test (LCT) in patients with Parkinson’s disease…
  • 2024 International Congress

    Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques

    M. Bradbury, M. Aumann, D. Claassen, D. Finkelstein (Newark, USA)

    Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…
  • 2024 International Congress

    Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models

    FAZ. Dustov, SEO. Seo (Tashkent, Uzbekistan)

    Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…
  • 2024 International Congress

    A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, G. Respondek, A. Monnet, N. Shariati, L. Rutten-Jacobs, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (Basel, Switzerland)

    Objective: To evaluate the effect on slowing motor progression and the safety of prasinezumab, a humanized monoclonal antibody targeting aggregated alpha-synuclein, in individuals with early…
  • 2024 International Congress

    Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor State Transitions Throughout the Day

    A. Ellenbogen, J. Ferreira, F. Stocchi, K. Kieburtz, A. Albanese, L. Adar, N. Vostokova, J. Pereira, R. Hauser (Farmington Hills, USA)

    Objective: Evaluate the effect of investigational ND0612 infusion on the daily number of, duration of, and transitions between PD motor states, as assessed by home…
  • « Previous Page
  • 1
  • …
  • 411
  • 412
  • 413
  • 414
  • 415
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley